Deficit of entropy modulation of the EEG in schizophrenia associated to cognitive performance and symptoms. A replication study

Schizophr Res. 2018 May:195:334-342. doi: 10.1016/j.schres.2017.08.057. Epub 2017 Sep 5.

Abstract

Spectral entropy (SE) is a measurement from information theory field that provides an estimation of EEG regularity and may be useful as a summary of its spectral properties. Previous studies using small samples reported a deficit of EEG entropy modulation in schizophrenia during cognitive activity. The present study is aimed at replicating this finding in a larger sample, to explore its cognitive and clinical correlates and to discard antipsychotic treatment as the main source of that deficit. We included 64 schizophrenia patients (21 first episodes, FE) and 65 healthy controls. We computed SE during performance of an odd-ball paradigm, at the windows prior (-300 to 0ms) and following (150 to 450ms) stimulus presentation. Modulation of SE was defined as the difference between post- and pre-stimulus windows. In comparison to controls, patients showed a deficit of SE modulation over frontal and central regions, also shown by FE patients. Baseline SE did not differ between patients and controls. Modulation deficit was directly associated with cognitive deficits and negative symptoms, and inversely with positive symptoms. SE modulation was not related to antipsychotic doses. Patients also showed a smaller change of median frequency (i.e., smaller slowing of oscillatory activity) of the EEG from pre- to post-stimulus windows. These results support that a deficit of fast modulation contributes to cognitive deficits and symptoms in schizophrenia patients.

Keywords: Electroencephalography; Median frequency; Midline; Schizophrenia; Shannon entropy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antipsychotic Agents / therapeutic use
  • Brain Mapping
  • Cognition Disorders / etiology*
  • Electroencephalography
  • Entropy
  • Event-Related Potentials, P300 / drug effects
  • Event-Related Potentials, P300 / physiology*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Principal Component Analysis
  • Schizophrenia / complications*
  • Schizophrenia / drug therapy
  • Spectrum Analysis
  • Young Adult

Substances

  • Antipsychotic Agents